| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Juris J Meier, Michael A Nauck, Nina Siepmann, Michael Greulich, Jens J Holst, Carolyn F Deacon, Wolfgang E Schmidt, Baptist Gallwit. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism: clinical and experimental. vol 52. issue 12. 2004-02-06. PMID:14669159. |
insulin secretion following the intravenous infusion of gastric inhibitory polypeptide (gip) is diminished in patients with type 2 diabetes and at least a subgroup of their first-degree relatives at hyperglycemic clamp conditions. |
2004-02-06 |
2023-08-12 |
human |
| Juris J Meier, Michael A Nauck, Nina Siepmann, Michael Greulich, Jens J Holst, Carolyn F Deacon, Wolfgang E Schmidt, Baptist Gallwit. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism: clinical and experimental. vol 52. issue 12. 2004-02-06. PMID:14669159. |
forty-five first-degree relatives of patients with type 2 diabetes and 33 matched control subjects were studied with (1) a 75-g oral glucose tolerance test (ogtt) and (2) an intravenous bolus injection of 20 pmol gip/kg bw with blood samples drawn over 30 minutes for determination of plasma glucose, insulin, c-peptide, and gip. |
2004-02-06 |
2023-08-12 |
human |
| Juris J Meier, Michael A Nauck, Nina Siepmann, Michael Greulich, Jens J Holst, Carolyn F Deacon, Wolfgang E Schmidt, Baptist Gallwit. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism: clinical and experimental. vol 52. issue 12. 2004-02-06. PMID:14669159. |
gip administration (20 pmol/kg bw) led to a significant rise of insulin and c-peptide concentrations in the first-degree relatives and control subjects (p <.0001), but there was difference between groups (p =.64 and p =.87, respectively). |
2004-02-06 |
2023-08-12 |
human |
| Juris J Meier, Michael A Nauck, Nina Siepmann, Michael Greulich, Jens J Holst, Carolyn F Deacon, Wolfgang E Schmidt, Baptist Gallwit. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism: clinical and experimental. vol 52. issue 12. 2004-02-06. PMID:14669159. |
integrated insulin and c-peptide responses after gip administration significantly correlated with the respective insulin and c-peptide responses after glucose ingestion (insulin, r = 0.78, p <.0001; c-peptide, r = 0.35, p =.0015). |
2004-02-06 |
2023-08-12 |
human |
| Juris J Meier, Michael A Nauck, Nina Siepmann, Michael Greulich, Jens J Holst, Carolyn F Deacon, Wolfgang E Schmidt, Baptist Gallwit. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism: clinical and experimental. vol 52. issue 12. 2004-02-06. PMID:14669159. |
therefore, a reduced gip-induced insulin secretion in patients with type 2 diabetes and their first-degree relatives at hyperglycemia is more likely due to a general defect of b-cell function than to a specific defect of the gip action. |
2004-02-06 |
2023-08-12 |
human |
| Victor A Gault, Finbarr P M O'Harte, Peter R Flat. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides. vol 37. issue 5. 2004-01-28. PMID:14607102. |
glucose-dependent insulinotropic polypeptide (gip or gastric inhibitory polypeptide) is a gastrointestinal hormone, which modulates physiological insulin secretion. |
2004-01-28 |
2023-08-12 |
mouse |
| W L Hall, D J Millward, P J Rogers, L M Morga. Physiological mechanisms mediating aspartame-induced satiety. Physiology & behavior. vol 78. issue 4-5. 2004-01-16. PMID:12782208. |
plasma cck, glp-1, glucose-dependent insulinotropic polypeptide (gip), glucose, and insulin were measured over 0-120 min. |
2004-01-16 |
2023-08-12 |
human |
| W L Hall, D J Millward, P J Rogers, L M Morga. Physiological mechanisms mediating aspartame-induced satiety. Physiology & behavior. vol 78. issue 4-5. 2004-01-16. PMID:12782208. |
however, gastric emptying rates, plasma cck, gip, insulin, and glucose concentrations were unaffected. |
2004-01-16 |
2023-08-12 |
human |
| V A Gault, F P M O'Harte, P Harriott, M H Mooney, B D Green, P R Flat. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia. vol 46. issue 2. 2003-12-05. PMID:12627321. |
effects of the novel (pro3)gip antagonist and exendin(9-39)amide on gip- and glp-1-induced cyclic amp generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that gip is the major physiological incretin. |
2003-12-05 |
2023-08-12 |
mouse |
| T Vilsbøll, F K Knop, T Krarup, A Johansen, S Madsbad, S Larsen, T Hansen, O Pedersen, J J Hols. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. The Journal of clinical endocrinology and metabolism. vol 88. issue 10. 2003-11-12. PMID:14557471. |
the effect of the insulinotropic incretin hormone, glucagon-like peptide-1 (glp-1), is preserved in typical middle-aged, obese, insulin-resistant type 2 diabetic patients, whereas a defective amplification of the so-called late-phase plasma insulin response (20-120 min) to glucose by the other incretin hormone, glucose-dependent insulinotropic polypeptide (gip), is seen in these patients. |
2003-11-12 |
2023-08-12 |
human |
| T Vilsbøll, F K Knop, T Krarup, A Johansen, S Madsbad, S Larsen, T Hansen, O Pedersen, J J Hols. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. The Journal of clinical endocrinology and metabolism. vol 88. issue 10. 2003-11-12. PMID:14557471. |
the aim of the present investigation was to evaluate plasma insulin and c-peptide responses to glp-1 and gip in five groups of diabetic patients with etiology and phenotype distinct from the obese type 2 diabetic patients. |
2003-11-12 |
2023-08-12 |
human |
| T Vilsbøll, F K Knop, T Krarup, A Johansen, S Madsbad, S Larsen, T Hansen, O Pedersen, J J Hols. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. The Journal of clinical endocrinology and metabolism. vol 88. issue 10. 2003-11-12. PMID:14557471. |
the early-phase (0-20 min) plasma insulin response tended to be enhanced by both gip and glp-1, compared with glucose alone, in all five groups. |
2003-11-12 |
2023-08-12 |
human |
| T Vilsbøll, F K Knop, T Krarup, A Johansen, S Madsbad, S Larsen, T Hansen, O Pedersen, J J Hols. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. The Journal of clinical endocrinology and metabolism. vol 88. issue 10. 2003-11-12. PMID:14557471. |
in contrast, the late-phase (20-120 min) plasma insulin response to gip was attenuated, compared with the plasma insulin response to glp-1, in all five groups. |
2003-11-12 |
2023-08-12 |
human |
| T Vilsbøll, F K Knop, T Krarup, A Johansen, S Madsbad, S Larsen, T Hansen, O Pedersen, J J Hols. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. The Journal of clinical endocrinology and metabolism. vol 88. issue 10. 2003-11-12. PMID:14557471. |
in conclusion, lack of gip amplification of the late-phase plasma insulin response to glucose seems to be a consequence of diabetes mellitus, characterizing most, if not all, forms of diabetes. |
2003-11-12 |
2023-08-12 |
human |
| Jan A Ehses, Vanbric R Casilla, Tim Doty, J Andrew Pospisilik, Kyle D Winter, Hans-Ulrich Demuth, Raymond A Pederson, Christopher H S McIntos. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology. vol 144. issue 10. 2003-10-29. PMID:12960055. |
the incretin glucose-dependent insulinotropic polypeptide (gip) is a major regulator of postprandial insulin secretion in mammals. |
2003-10-29 |
2023-08-12 |
Not clear |
| V A Gault, P Harriott, P R Flatt, F P M O'Hart. Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide. Bioscience reports. vol 22. issue 5-6. 2003-09-16. PMID:12635849. |
synthetic fragment peptides of glucose-dependent insulinotropic polypeptide (gip) were evaluated for their ability to elevate cellular camp production and stimulate insulin secretion. |
2003-09-16 |
2023-08-12 |
Not clear |
| V A Gault, P Harriott, P R Flatt, F P M O'Hart. Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide. Bioscience reports. vol 22. issue 5-6. 2003-09-16. PMID:12635849. |
in the clonal pancreatic beta-cell line, brin-bd11, gip(1-16) demonstrated weak insulin releasing activity compared with native gip. |
2003-09-16 |
2023-08-12 |
Not clear |
| V A Gault, P Harriott, P R Flatt, F P M O'Hart. Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide. Bioscience reports. vol 22. issue 5-6. 2003-09-16. PMID:12635849. |
in contrast, gip(4-42) and gip (17-30) weakly antagonized the insulin releasing activity of the native peptide (23 +/- 6%; p<0.05 and 11 +/- 3%, respectively). |
2003-09-16 |
2023-08-12 |
Not clear |
| Victor A Gault, Peter R Flatt, Finbarr P M O'Hart. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochemical and biophysical research communications. vol 308. issue 2. 2003-09-11. PMID:12901855. |
glucose-dependent insulinotropic polypeptide (gip) is a key incretin hormone, released postprandially into the circulation in response to feeding, producing a glucose-dependent stimulation of insulin secretion. |
2003-09-11 |
2023-08-12 |
Not clear |
| V A Gault, N Irwin, P Harriott, P R Flatt, F P M O'Hart. DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP. Cell biology international. vol 27. issue 1. 2003-08-28. PMID:12713798. |
dpp iv resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (ser2-asp13)gip. |
2003-08-28 |
2023-08-12 |
Not clear |